Nosakhare Paul Ilerhunmwuwa

Nosakhare Paul Ilerhunmwuwa

Auto-generated profile, based on publicly available information

Nosakhare Paul Ilerhunmwuwa

Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NINosakhare Paul Ilerhunmwuwa
Nosakhare Paul Ilerhunmwuwa
AKAbul Hasan Shadali Abdul Khader
Abul Hasan Shadali Abdul Khader
CSCalvin Smith
Calvin Smith
ECEdward R Scheffer Cliff
Edward R Scheffer Cliff
CBChristopher Booth
Christopher Booth
GMGhulam Rehman Mohyuddin
Ghulam Rehman Mohyuddin
Background: Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic review, we assessed all randomized controlled trials (RCTs) investigating dietary interventions for cancer patients, examining the range of interventions, endpoints, patient populations, and results. Methods: This systematic review identified all RCTs conducted before January 2023 testing dietary interventions in patients with cancer. Assessed outcomes included quality of life, functional outcomes, clinical cancer measurements (eg, progression-free survival, response rates), overall survival, and translational endpoints (eg, inflammatory markers). Results: In total, 252 RCTs were identified involving 31 067 patients. The median sample size was 71 (interquartile range 41 to 118), and 80 (32%) studies had a sample size greater than 100. Most trials (n = 184, 73%) were conducted in the adjuvant setting. Weight or body composition and translational endpoints were the most common primary endpoints (n = 64, 25%; n = 52, 21%, respectively). Direct cancer measurements and overall survival were primary endpoints in 20 (8%) and 7 (3%) studies, respectively. Eight trials with a primary endpoint of cancer measurement (40%) met their endpoint. Large trials in colon (n = 1429), breast (n = 3088), and prostate cancer (n = 478) each showed no effect of dietary interventions on endpoints measuring cancer. Conclusion: Most RCTs of dietary interventions in cancer are small and measure nonclinical endpoints. Although only a small number of large RCTs have been conducted to date, these trials have not shown an improvement in cancer outcomes. Currently, there is limited evidence to support dietary interventions as a therapeutic tool in cancer care.

30 December 2022 in Cureus
Verified
Journal Article
Open access
NINosakhare Ilerhunmwuwa
Nosakhare Ilerhunmwuwa
ESEphrem Sedeta
Ephrem Sedeta
MWMustafa Wasifuddin
Mustafa Wasifuddin
NHNarek Hakobyan
Narek Hakobyan
HAHenry O Aiwuyo
Henry O Aiwuyo
JWJenchin Wang
Jenchin Wang
Cardiac tamponade is a rare presentation in breast cancer and may be associated with poor prognosis. In this article, we reviewed the characteristics and survival outcomes of patients with breast cancer who developed cardiac tamponade. Three databases (PubMed, EMBASE and SCOPUS) were searched for relevant articles published from 1978 to 2022 and 16 articles were identified comprising 64 cases. The median age of the cases was 52 years. Cardiac tamponade was diagnosed with echocardiogram or computerized tomography of the chest or both in 91.9%, 1.6% and 6.5% of the cases, respectively. Cytology of the pericardial fluid was done in 90.5% of the cases while biopsy in addition to cytology was done in 9.5% of cases. Tamponade was proven to be malignant in 97.4% of the cases. The initial treatment for tamponade was pericardiocentesis. Adjunct therapies ranged from the insertion of a pericardial window, pericardiectomy, radiotherapy and chemotherapy. The median time from the first treatment of breast cancer to the onset of tamponade was 24 months while the median survival following diagnosis of tamponade was 13 months. There was no significant correlation (spearman rank-sum correlation coefficient = 0.35, p = 0.165) between time to tamponade (interval time from the first diagnosis of breast cancer and the onset of cardiac tamponade) and survival. Cardiac tamponade may adversely affect survival in patients with breast cancer. Early diagnosis with echocardiogram and cytology may guide management and expectations. Further observational studies are needed to determine the predictors of cardiac tamponade and optimal treatment in patients with breast cancer.

18 January 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
NINosakhare Paul Ilerhunmwuwa
Nosakhare Paul Ilerhunmwuwa
RGRobert Goldspring
Robert Goldspring
SPSimon Page
Simon Page
RGRavikanth Gouni
Ravikanth Gouni
An 85-year-old man was referred to endocrinology following the discovery of an incidental pituitary mass on cranial imaging which was thought to be a non-functioning adenoma during an admission with headaches, lethargy, confusion and hyponatraemia. He had a history of Hürthle cell carcinoma of the thyroid treated with total thyroidectomy, ablative radioiodine therapy and thyroxine replacement. Subsequently, he developed metastatic spread to the neck, lungs and skeleton. About 9 months later, the patient had deterioration of vision. MRI showed a rapidly expanding pituitary mass with compression of the optic chiasm. Biochemical investigations confirmed hypocortisolism and hypogonadism. The patient underwent trans-sphenoidal resection of the pituitary mass followed by external beam radiotherapy to the pituitary bed. Histopathology confirmed a metastatic deposit of Hürthle cell carcinoma, which is a rare and aggressive variant of follicular thyroid carcinoma.

29 December 2022 in Cureus
Verified
Journal Article
Open access
BTBeatrice E Torere
Beatrice E Torere
HAHenry O Aiwuyo
Henry O Aiwuyo
NINosakhare Ilerhunmwuwa
Nosakhare Ilerhunmwuwa
HRHafiz M. Raza
Hafiz M. Raza
JTJiahuai Tan
Jiahuai Tan
MWMustafa Wasifuddin
Mustafa Wasifuddin
Signet ring cell carcinoma (SRCC) is a poorly differentiated mucin-producing adenocarcinoma with greater than 50% signet ring cells. It commonly arises from the gastrointestinal (GI) tract and rarely from extraintestinal organs. This is a rare case of a young African American female who presented with metastatic spread of signet ring cell gastric cancer (pleural and lymph nodal involvement) as the initial presentation of SRCC. Knowledge of the various clinical manifestations of SRCC can help with its early diagnosis, and there is a high need for detailed physical examination, early referral, and prompt treatment in patients with SRCC.

6 August 2023 in Leukemia Research Reports
Verified
Journal Article
Open access
NINosakhare Paul Ilerhunmwuwa
Nosakhare Paul Ilerhunmwuwa
MWMustafa Wasifuddin
Mustafa Wasifuddin
HBHenry Becerra
Henry Becerra
ARAditya Keerthi Rayapureddy
Aditya Keerthi Rayapureddy
JWJen Chin Wang
Jen Chin Wang

21 July 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
NINosakhare Paul Ilerhunmwuwa
Nosakhare Paul Ilerhunmwuwa
LILawrence Inyang
Lawrence Inyang
MWMustafa Wasifuddin
Mustafa Wasifuddin
HAHenry Aiwuyo
Henry Aiwuyo
MTMuhammad Tahir
Muhammad Tahir
JWJenchin Wang
Jenchin Wang